Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 4/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025566 | 1.00 | CYP1A2 (0.44) | CYP1A2L3MBTL1RAB9ALMNAPOLB | |
| SCHEMBL13220018 | 0.96 | CYP1A2 (0.43) | CYP1A2L3MBTL1RAB9ALMNAPOLB | |
| SCHEMBL13355491 | 0.96 | CYP1A2 (0.43) | CYP1A2L3MBTL1RAB9ALMNAPOLB | |
| SCHEMBL3031624 | 0.96 | CYP1A2 (0.43) | CYP1A2L3MBTL1RAB9ALMNAPOLB | |
| SCHEMBL3042367 | 0.95 | CYP1A2 (0.42) | CYP1A2L3MBTL1RAB9ALMNAPOLB | |
| SCHEMBL13220025 | 0.95 | CYP1A2 (0.42) | CYP1A2L3MBTL1RAB9ALMNAPOLB | |
| SCHEMBL8283643 | 0.84 | CYP1A2 (0.41) | CYP1A2L3MBTL1RAB9ALMNAPOLB | |
| SCHEMBL28639087 | 0.82 | LMNA (0.42) | L3MBTL1RAB9ALMNAPOLBTSHR | |
| SCHEMBL11731563 | 0.81 | RAB9A (0.36) | L3MBTL1RAB9ALMNAPOLBTSHR | |
| SCHEMBL1127670 | 0.77 | L3MBTL1 (0.63) | CYP1A2L3MBTL1RAB9ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210640-A1 | BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF | JIANGSU HENGRUI MEDICINE CO. LTD. (CN) | 2010-08-19 | — | — | US | disclosed |
| EP-2189451-A1 | BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2010-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210640-A1 | BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF | HTR4, HTR5A, TPH1 | CYP1A2 241/4885L3MBTL1 4866/4885RAB9A 3358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.